Patents by Inventor Pinaki Panigrahi

Pinaki Panigrahi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20040096427
    Abstract: A composition and method for treating and preventing gastro-intestinal injury are disclosed. The composition includes a combination of Gram (+) bacteria, in particular Lactobacillus and/or Bifidobacteria, and glutamine. The method involves orally or naso-gastrically administering a composition containing Gram (+) bacteria, in particular Lactobacillus, and glutamine. The composition, which blocks translocation of bacterial agents such as Gram (−) bacteria, other infectious agents, toxins, chemicals and injurious substances, may be used in the prevention and treatment of symptoms and/or disease that result from translocation of Gram (−) bacteria, including inflammation in the gastro-intestinal tract, Neonatal Necrotizing Enterocolitis (NEC) and bacterial sepsis.
    Type: Application
    Filed: October 2, 2003
    Publication date: May 20, 2004
    Inventor: Pinaki Panigrahi
  • Patent number: 6682744
    Abstract: Strains of Lactobacilli having the ability to reduce or block pro-inflammatory cytokines and also to induce anti-inflammatory cytokines are disclosed. These strains may be used to prepare therapeutic agents that reduce inflammation. Lactobacillus secreted proteins, carbohydrates and lipids are also disclosed. The Lactobacillus secretions, which block translocation of bacterial agents such as Gram (−) bacteria, other infectious agents, toxins, chemicals and injurious substances, may be used in the prevention and treatment of inflammation caused by bacterial translocation and injury and in treating gastrointestinal dysfunctions.
    Type: Grant
    Filed: August 9, 2000
    Date of Patent: January 27, 2004
    Assignee: University of Maryland
    Inventor: Pinaki Panigrahi
  • Patent number: 6132710
    Abstract: Gastrointestinal tissue injury and infections are treated by orally administering Lactobacilli strains. The Lactobacilli strains prevent neonatal necrotizing enterocolitis tissue injury and necrotizing enterocolitis in preterm infants. Preterm infants, full-term infants, children and adults as well as animals may be given the Lactobacilli strains. The strains are Lactobacillus salivarius strain ATCC 202196 and Lactobacillus plantarum strain ATCC 202195. Further, the strains may be given individually or as a combination of the two strains. In addition, the strains are useful in treating diarrhea. The Lactobacilli strains normalize and balance bacterial milieu in the gastro-intestinal tract. The Lactobacilli strains may be in lyophilized capsule form. The capsule may be an enteric coated slow-release microcapsule. The Lactobacilli strains may also be administered by means of a naso-gastric tube, especially for preterm infants.
    Type: Grant
    Filed: March 17, 1997
    Date of Patent: October 17, 2000
    Assignee: ProBiotix, Inc.
    Inventors: Pinaki Panigrahi, Ira H. Gewolb, J. Glenn Morris, Jr.
  • Patent number: 5981590
    Abstract: A method of preventing necrotizing tissue injury in the gastrointestinal tract comprising orally administering glutamine is disclosed. Glutamine protects tissues along the gastrointestinal tract by blocking translocation of bacterial agents such as gram (-) bacteria, other infectious agents, toxins, chemicals and injurious substances. The intraluminal/apical presence of the glutamine optimizes mucosal defense and increases nutrient absorption. Enteral glutamine is useful in treating neonatal necrotizing enterocolitis for reducing inflammation caused by bacterial translocation and injury. Oral glutamine is also useful in treating gastrointestinal dysfunctions. When glutamine is orally administered, it coats gastrointestinal mucosa thereby treating infectious and/or inflammatory conditions of the gastrointestinal tract. It is useful in treating pathologic conditions with lowered transepithelial electrical resistance (TEER) by acting as a curative agent.
    Type: Grant
    Filed: March 17, 1997
    Date of Patent: November 9, 1999
    Assignee: ProBiotix, Inc.
    Inventors: Pinaki Panigrahi, Karoly Horvath, Ira H. Gewolb